Bristol Myers passes on two Exscientia oncology candidates, but biotech to move them into clinic next year
Exscientia said it expanded its pipeline Tuesday morning, but the biotech is doing so without the help of a yearslong partner: Bristol Myers Squibb.
The Big Pharma has decided not to move forward with two oncology development candidates, Exscientia said. The AI-driven UK biotech plans to start testing the compounds in the clinic next year on its own, CEO Andrew Hopkins told Endpoints News.
“We took this as part of a routine portfolio prioritization happening in BMS and other Big Pharma at the moment,” Hopkins said.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.